Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations

Tassanee Lerksuthirat; Sunisa Prasopporn; Rakkreat Wikiniyadhanee; Sermsiri Chitphuk; Wasana Stitchantrakul; Paravee Owneium; Siwanon Jirawatnotai; Donniphat Dejsuphong

doi:10.1002/1878-0261.13683

Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations

Tassanee Lerksuthirat
, Sunisa Prasopporn
, Rakkreat Wikiniyadhanee
, Sermsiri Chitphuk
, Wasana Stitchantrakul
, Paravee Owneium
, Siwanon Jirawatnotai
, Donniphat Dejsuphong

Research Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Siriraj Hospital
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Ramathibodi Hospital
Research Center
Khon Kaen University
Phramongkutklow College of Medicine
Chakri Naruebodindra Medical Institute

Research output: Contribution to conference › Poster

3 Citations (Scopus)

Original language	English
DOIs	https://doi.org/10.1002/1878-0261.13683
Publication status	Published - 2024
Event	The 2024 Annual Congress of the European Association for Cancer Research - Rotterdam Ahoy, Rotterdam, Netherlands Duration: 10 Jun 2024 → 13 Jun 2024 https://2024.eacr.org/

Conference

Conference	The 2024 Annual Congress of the European Association for Cancer Research
Abbreviated title	EACR 2024
Country/Territory	Netherlands
City	Rotterdam
Period	10/06/24 → 13/06/24
Internet address	https://2024.eacr.org/

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/1878-0261.13683Licence: CC BY-NC-ND

Cite this

Lerksuthirat, T., Prasopporn, S., Wikiniyadhanee, R., Chitphuk, S., Stitchantrakul, W., Owneium, P., Jirawatnotai, S., & Dejsuphong, D. (2024). Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations. Poster session presented at The 2024 Annual Congress of the European Association for Cancer Research, Rotterdam, Netherlands. https://doi.org/10.1002/1878-0261.13683

@conference{069a6a5ba7554ece9c98cdfefc6ec7b0,

title = "Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations",

author = "Tassanee Lerksuthirat and Sunisa Prasopporn and Rakkreat Wikiniyadhanee and Sermsiri Chitphuk and Wasana Stitchantrakul and Paravee Owneium and Siwanon Jirawatnotai and Donniphat Dejsuphong",

year = "2024",

doi = "10.1002/1878-0261.13683",

language = "English",

note = "The 2024 Annual Congress of the European Association for Cancer Research, EACR 2024 ; Conference date: 10-06-2024 Through 13-06-2024",

url = "https://2024.eacr.org/",

}

Lerksuthirat, T, Prasopporn, S, Wikiniyadhanee, R, Chitphuk, S, Stitchantrakul, W, Owneium, P, Jirawatnotai, S & Dejsuphong, D 2024, 'Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations', The 2024 Annual Congress of the European Association for Cancer Research, Rotterdam, Netherlands, 10/06/24 - 13/06/24. https://doi.org/10.1002/1878-0261.13683

Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations. / Lerksuthirat, Tassanee; Prasopporn, Sunisa; Wikiniyadhanee, Rakkreat et al.
2024. Poster session presented at The 2024 Annual Congress of the European Association for Cancer Research, Rotterdam, Netherlands.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations

AU - Lerksuthirat, Tassanee

AU - Prasopporn, Sunisa

AU - Wikiniyadhanee, Rakkreat

AU - Chitphuk, Sermsiri

AU - Stitchantrakul, Wasana

AU - Owneium, Paravee

AU - Jirawatnotai, Siwanon

AU - Dejsuphong, Donniphat

PY - 2024

Y1 - 2024

UR - https://nwm.covr.be/cmEpostersV2/#/PosterDetail/1846

U2 - 10.1002/1878-0261.13683

DO - 10.1002/1878-0261.13683

M3 - Poster

T2 - The 2024 Annual Congress of the European Association for Cancer Research

Y2 - 10 June 2024 through 13 June 2024

ER -

Lerksuthirat T, Prasopporn S, Wikiniyadhanee R, Chitphuk S, Stitchantrakul W, Owneium P et al.. Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations. 2024. Poster session presented at The 2024 Annual Congress of the European Association for Cancer Research, Rotterdam, Netherlands. doi: 10.1002/1878-0261.13683

Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations

Conference

UN SDGs

Access to Document

Other files and links

DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines

Oncology Letters (Journal)

Discover Oncology (Journal)

Okinawa Microscopy Workshop 2024

DOJIN NEWS

High Performance Computer

MURA-RC-MiniCore: Microscopy

Upright Fluorescence Microscope

Cite this

Investigation of the combined use of PARP inhibitors for targeted therapy in cholangiocarcinoma with different DNA damage response mutations

Conference

UN SDGs

Access to Document

Other files and links

Research output

Activities

Press/Media

Equipment

Cite this